Monitor for DURIPANC data readouts in Q1 2027 (clinical benefit) and Q3 2027 (overall survival). The termination of the equity line increases financing risk; the company may need to seek alternative funding or further dilute. Watch for any partnership or government funding announcements.
Price Chart
Executive Summary
AIM ImmunoTech reported Q2 2026 net loss of $(3.8M) or $(0.43) per share, a 258% miss vs consensus of $(0.12). The company completed enrollment in its Phase 2 DURIPANC pancreatic cancer trial but has no revenue and faces financing risk after terminating its equity line, with $9.9M cash providing a limited runway.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $(3.8M) vs $(2.8M) in Q2 2025.
- EPS $(0.43) missed consensus $(0.12) by 258%.
- Cash and cash equivalents at June 30, 2026 were $9.9M, up from $3.0M at December 31, 2025.
- Completed enrollment and Ampligen dosing in the Phase 2 DURIPANC metastatic pancreatic cancer trial.
- Terminated Equity Distribution Agreement with Maxim Group, eliminating a key funding source.
- Research and development expenses fell to $589K from $1.2M YoY; G&A expenses rose to $2.9M from $1.5M.
Financial Impact
Net loss widened to $(3.8M) from $(2.8M) YoY; cash position strengthened to $9.9M but quarterly burn rate of ~$3.5M suggests ~2.8 quarters of runway.
Risk Factors
- Cash runway limited to ~2.8 quarters at current burn rate if no additional financing secured.
- No revenue and no near-term commercialization prospects.
- Dependence on successful Phase 2/3 data for pancreatic cancer; clinical trial risk.
- Loss of equity line may force dilutive or distressed financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3341836 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers